Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients.

Journal Article (Clinical Trial;Journal Article)

BACKGROUND: Recombinant human stem-cell factor (SCF), a cytokine acting on hematopoietic progenitor cells, has potential for the treatment of several hematologic and oncologic disorders. In a hematology-oncology phase I trial of SCF, several patients had cutaneous hyperpigmentation at the SCF subcutaneous injection sites. OBJECTIVE: Our purpose was to investigate the pathogenesis of this hyperpigmentation phenomenon. METHODS: Skin biopsy specimens were obtained before, at the completion of, and after SCF therapy and were processed for histology, immunohistology, and electron microscopy. RESULTS: Skin at the site of SCF injection had an increased number of melanocytes, increased melanocytic dendrite extension, and melanin as compared with noninjected tissue. Immunohistochemical stains revealed an increase in staining with melanocyte-specific monoclonal antibodies HMB-45 and NKI/beteb, and a monoclonal antibody to the receptor for SCF, c-kit. CONCLUSION: Subcutaneous injection of SCF results in hyperplasia of melanocytes. SCF may be useful in the treatment of melanocytopenic disorders, but caution may be necessary in patients with disorders of melanocyte proliferation.

Full Text

Duke Authors

Cited Authors

  • Grichnik, JM; Crawford, J; Jimenez, F; Kurtzberg, J; Buchanan, M; Blackwell, S; Clark, RE; Hitchcock, MG

Published Date

  • October 1995

Published In

Volume / Issue

  • 33 / 4

Start / End Page

  • 577 - 583

PubMed ID

  • 7545704

International Standard Serial Number (ISSN)

  • 0190-9622

Digital Object Identifier (DOI)

  • 10.1016/0190-9622(95)91274-6


  • eng

Conference Location

  • United States